Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma

HONGJUN WANG1,5*, YING FENG2*, ZHAOSHI BAO3,5*, CHUANLU JIANG1,5*, WEI YAN3,5, YONGZHI WANG3,5, CHUANBAO ZHANG3,5, YANWEI LIU3,5*, QUANGENG ZHANG2, WEI ZHANG3,5 and CHUANLU JIANG1,5

1Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086; 2Department of Immunology, Institute of Basic Medical Sciences, Capital Medical University, Beijing 100069; 3Beijing Neurosurgical Institute, Beijing 100050; 4Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China; 5Chinese Glioma Cooperative Group (CGCG)

Received May 29, 2013; Accepted July 2, 2013

DOI: 10.3892/or.2013.2706

Abstract. In order to more thoroughly analyze aberrant DNA methylation in glioma, we applied a large cohort methylation microarray including 119 glioma samples. Six genes, ADCY1, KAZALD1, KLF4, SLMAP, TETRAN and TP53INP1, were screened out through significance analysis of microarray (SAM), survival Cox-regression and certain other pre-set conditions. We focused on the KAZALD1 oncogene. KAZALD1, also known as IGFBP-rP10, belongs to the IGFBP family. We found that KAZALD1 was hypomethylated in high-grade glioma (anaplastic gliomas and glioblastomas) compared to low-grade glioma (astrocytoma, oligodendrocytoma and oligoastrocytoma) using methylation microarrays (P<0.001). Immunohistochemistry (IHC) of 91 glioma samples showed that the KAZALD1 expression scores of high-grade glioma samples were higher compared to the scores of low-grade gliomas (P<0.001). In high-grade gliomas, overall survival (OS) was shorter for patients with KAZALD1 hypomethylation or overexpression compared to those without. Decreased KAZALD1 expression in glioma inhibited cell proliferation and invasion both in vitro and in vivo. On the basis of these observations and the results from subset analysis, it is reasonable to conclude that KAZALD1 promoter hypomethylation is an important prognostic biomarker in glioma. KAZALD1 promotes glioma malignant progression through invasion and proliferation.

Introduction

Gliomas are the most common and most aggressive types of primary brain tumor in humans. Despite recent advances in treatment by a combination of surgery and chemotherapy and/or radiotherapy, the prognosis of malignant glioma remains extremely poor. Glioblastoma (GBM) is the most common and malignant glioma, and has a median survival time of approximately one year (1-7). In the United States, 75% of glioma patients die within 5 years of diagnosis (8). There is, therefore, an urgent need for the development of a prognostic biomarker for this disease.

To date, a considerable amount of research has discovered that epigenetic mechanisms play an important role in tumors. Aberrant epigenetic mechanisms, such as promoter hyper/hypomethylation, histone modifications, or non-coding RNA expression, are key in tumor formation (9). Moreover, DNA methylation is typically a more stable and inheritable epigenetic pattern that can persist for several cell generations, which potentially broadens its practical applicability in the clinic (10). Changes in DNA methylation patterns are an important hallmark of tumor development and progression (11). Although the role of hypermethylation in the silencing of tumor suppressor genes is now well-documented (12), a reduction in the level of methylation also contributes to neoplastic progression in numerous types of human cancer, including gliomas (13,14).

KAZALD1 is also known as IGFBP-rP10, BONO1, FKS28 or FKS40. This gene encodes a secreted member of the insulin growth factor-binding protein (IGFBP) superfamily. It contains an N-terminal insulin growth factor-binding domain, a central Kazal-type serine protease...
manufacturer's protocol. DNA concentration and quality were measured using the QIAamp DNA Mini kit (Qiagen) according to the manufacturer's instructions. Genomic DNA was isolated from frozen tumor tissues of the percentage of tumor cells before DNA extraction. A hematoxylin and eosin-stained frozen section was prepared for assessment of molecular findings with disease outcome emphasized the prognostic relevance of KAZALD1 methylation and expression in glioma patients. Functional assays in glioma cell lines were also performed.

Materials and methods

Patients and samples. All patients were from the Chinese Glioma Genome Atlas (CGGA). The patients selected in the present study underwent surgical resection between January 2006 and December 2010 and subsequently received concomitant and adjuvant temozolomide and radiotherapy. Clinical data, including patient age at diagnosis, gender and preoperative Karnofsky performance status (KPS) score were obtained from the medical records. Overall survival (OS) time, defined as the period from operation to mortality, was calculated mainly when patients visited the clinics or by phone interview with patients and/or their relatives. Patients who succumbed to non-primary diseases were excluded (18). Tumor tissue samples were obtained by surgical resection before the treatment with radiation and chemotherapy. Respective specimens were snap-frozen and stored in liquid nitrogen until nucleic acid extraction. The present study was approved by the Ethics Committee of the Capital Medical University, and written informed consent was obtained from all patients. Only samples with >80% tumor cells were selected.

DNA extraction. All tissue samples were immediately snap-frozen in liquid nitrogen after surgery. A hematoxylin and eosin-stained frozen section was prepared for assessment of the percentage of tumor cells before DNA extraction. Genomic DNA was isolated from frozen tumor tissues using the QIAamp DNA Mini kit (Qiagen) according to the manufacturer's protocol. DNA concentration and quality were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX, USA).

Genome-wide DNA methylation profiling. A series of 119 glioma samples (63 low-grade gliomas, 33 anaplastic gliomas and 23 glioblastomas) were measured by methylation microarray. We used the Illumina Infinium Human Methylation 27 BeadChips (Illumina Inc.), as previously described (19). The BeadChip contains 27,578 highly informative CpG sites covering more than 14,000 human RefSeq genes. This allows researchers to interrogate all these sites per sample at a single nucleotide resolution. Bisulfite modification of DNA, chip processing and data analysis were performed following the manufacturer's manual at the Wellcome Trust Centre for Human Genetics Genomics Laboratory (Oxford, UK). The array results were analyzed with the BeadStudio software (Illumina).

Immunohistochemistry. Immunohistochemistry (IHC) was performed as previously described (20). Briefly, surgical biopsies from the patients above were fixed in formalin, routinely processed and paraffin-embedded. Five micronthick sections were prepared, and immunohistochemical staining with streptavidin-biotin immunoperoxidase assay was performed using goat polyclonal antibody to KAZALD1 (Santa Cruz Biotechnology). The degree of immunostaining of sections was viewed and scored separately by two independent investigators. The scores were determined by combining the proportion of positively stained tumor cells and the intensity of staining. The proportion of positively stained tumor cells was graded as follows: 0, no positive tumor cells; 1, <5% positive tumor cells; 2, 5-20% positive tumor cells; and 3, >20% positive tumor cells (5). The intensity of staining was recorded on a scale of 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown) and 3 (strong staining, brown). The staining index was calculated as follows: staining index = staining intensity x proportion of positively stained tumor cells. High KAZALD1 expression was defined as a staining index score >6, while low expression was defined as a staining index ≤6.

Cell lines and cell culture. The human glioblastoma cell lines LN229 and U251 were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science, Shanghai, China. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and incubated at 37°C in 5% CO2. Upon 80% confluency, cells were starved in DMEM with 1% FBS for 24 h and maintained in this low-serum condition for the course of the treatment.

KAZALD1 gene knockdown by siRNA. Specific oligos targeting the KAZALD1 gene were selected (Origene Technologies, Inc, Rockville, MD, USA). siRNA1, the most efficient one, screened from three siRNAs, was used to knockdown KAZALD1 (sequence, 5'-GCAUGGCACTCAUAACGUUUCUA-3'). Logarithmically growing cells were seeded at a density of 104 cells per 6-cm dish and transfected with 5 μmol KAZALD1 siRNA using Lipofectamine® 2000 (Invitrogen), according to the manufacturer's instructions.
Forty-eight hours later, cells were used for in vitro functional assays as described below.

Western blot analysis. Following the cell treatment, cell lysates were prepared via lysis buffer, electrophoresed onto SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were probed with rabbit antibodies against KAZALD1 (Santa Cruz Biotechnology) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (A-3; Santa Cruz Biotechnology) at dilutions of 1:1,000. Blots were detected with horseradish peroxidase-labeled anti-goat antibodies (1:5,000 dilution), developed using enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia, Buckinghamshire, UK).

Transwell invasion assay. The transwell invasion assay was carried out in 24-well cell culture chambers using transwell inserts (Corning Life Sciences, Corning, NY, USA) with 8 µm pore membrane precoated with matrigel (BD Biosciences, San Jose, CA, USA). LN229 and U251 cells were plated at the density of 1x10^4 per upper well in 200 µl culture medium (DMEM, no FBS), control group and siRNA group, respectively. The lower chamber was filled with 500 µl medium (DMEM, 12% FBS). The cells were allowed to invade for 24 h, after which time the non-invading cells with Matrigel matrix were removed from the upper surface of the membrane by scrubbing with a cotton-tipped swab. Cells on the lower surface of the filter were fixed for 30 min in methanol and glacial acetic acid mixture (3:1), air-dried briefly and stained with crystal violet. The mean number of invaded cells was counted from five preselected microscopic fields at x200 magnification. All experiments were performed in triplicate.

Colonies formation assay. LN229 and U251 cells were transfected with siRNA or a negative control for 48 h and were then plated into six orifice plates (1,000 per orifice) and transfected with siRNA one more time on the 6th day. On the 12th day, plates were washed with PBS and stained with crystal violet. The number of colonies with >30 cells was counted. The colonies were counted manually using a microscope.

Nude mouse tumor xenograft model and siRNA of KAZALD1 treatment. U251 glioma cells were subcutaneously injected into 5-week-old female nude mice (Cancer Institute of the Chinese Academy of Medical Science). When the tumor volume reached 50 mm^3, mice were randomly divided into two groups (six mice per group). Each group was treated with siRNA of KAZALD1 or negative control oligo in 10 µl Lipofectamine through local injection of the xenograft tumor at multiple sites. The treatment was performed once every 3 days for 15 days. The tumor volume was measured with a caliper twice a week, using the following formula: volume = length x width^2/2.

Statistical analysis. Significance analysis of microarrays (SAM) was used for genes significantly differently methylated between high-grade and low-grade gliomas. Cox-regression was performed using Matleb software. A two-sided \( \chi^2 \) test was performed using SPSS 13.0. Kaplan-Meier survival curves were obtained and differences in the OS were tested using the log-rank test (GraphPad Prism 5). Differences of tumor cell invasion and colony formation number between treated and control groups were analyzed by t-test. \( P<0.05 \) was considered to indicate a statistically significant result.

Results

Gene screening. The methylation microarray from CGGA contains 27,578 highly informative CpG sites covering more than 14,475 human RefSeq genes. Following SAM analysis between high- and low-grade gliomas, with FDR<0.2, 306 probes were screened out. Then, by survival Cox-regression analysis using Metlab software, 25 probes (25 genes) were left. For univariate analysis validation, we performed t-test and Kaplan-Meier survival curve and log-rank test, after which, 12 probes (12 genes) remained. We further searched for the CpG islands upstream of the promoter, 6 genes were in the list in the end. These 6 genes were ADCY1, KAZALD1, KLF4, SLMAP, TETRAN and TP53INP1. We selected the oncogene KAZALD1 (Fig. 1).

High grade and poor prognosis association of KAZALD1 hypomethylation in CGGA data. The methylation level of KAZALD1 was measured in a series of 119 glioma samples (63 low-grade gliomas, 33 anaplastic gliomas and 23 glioblastomas) via microarray. KAZALD1 was significantly hypomethylated in high-grade gliomas compared to low-grade gliomas (\( P<0.001 \)). The correlation between KAZALD1 methylation and OS was measured through Kaplan-Meier survival curve analysis and log-rank test. KAZALD1 methylation was inversely correlated with OS in the high-grade glioma samples (\( P=0.002 \)) (Fig. 2B).

Patients with low-methylation level had a median OS of 544 days compared to 958 days in patients with high methylation level (Table I). Preoperative KPS score was also correlated with OS (\( P=0.004 \)). There was no significant association
with age, gender and OS. The multivariate Cox proportional hazards model, after adjusting for age, KPS score, identified hypomethylation of KAZALD1 as an independent unfavorable prognostic factor for OS (P=0.009).

Expression of KAZALD1 is relative to glioma grade progression and confers a poor prognosis of high KAZALD1 expression in high-grade glioma patients. We performed immunohistochemical staining in 91 glioma samples from mainland Han Chinese glioma patients. The 91 patients consisted of 30 patients with astrocytoma (A, WHO grade II), 20 with anaplastic astrocytoma (AA, WHO grade III) and 41 with glioblastoma multiforme (GBM, WHO grade IV). We analyzed the correlation between KAZALD1 protein expression and histological staging of gliomas, which showed KAZALD1 expression ranged from low to high along with grade progression of gliomas (P<0.01; Fig. 3A). Survival analysis showed that patients with high KAZALD1 expression had significantly shorter OS (P<0.001) than those with low expression in high-grade glioma patients (Fig. 3B). We also confirmed there was no KAZALD1 expression in normal brain tissue by IHC (Fig. 4).

Patients with high KAZALD1 expression had median OS time of 295 days compared to 660 days in patients with low KAZALD1 expression (Table II). Preoperative KPS score was also correlated with OS (P=0.022). There were no significant associations with age, gender and OS. The multivariate Cox proportional hazards model, after adjusting for age, KPS score, identified high KAZALD1 expression as an independent unfavorable prognostic factor for OS (HR, 4.096; P=0.001).

KAZALD1 promotes invasion and proliferation of LN229 and U251 cell lines. Following siRNA knockdown of KAZALD1 in two cell lines, LN229 and U251, we validated its expres-
Table II. Variables related to OS in 61 high-grade glioma validated samples (58 survivals were available): univariate and multivariate analysis.

<table>
<thead>
<tr>
<th>Variables</th>
<th>No. of patients</th>
<th>Median OS (days)</th>
<th>95% CI (days)</th>
<th>P-value</th>
<th>Relative risk</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38</td>
<td>493</td>
<td>339-647</td>
<td>0.410</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>20</td>
<td>362</td>
<td>200-523</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>29</td>
<td>570</td>
<td>466-674</td>
<td>0.192</td>
<td>1.207</td>
<td>0.541-2.689</td>
<td>0.646</td>
</tr>
<tr>
<td>&gt;50</td>
<td>29</td>
<td>354</td>
<td>332-376</td>
<td></td>
<td>0.519</td>
<td>0.207-1.300</td>
<td>0.161</td>
</tr>
<tr>
<td>KPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;80</td>
<td>37</td>
<td>376</td>
<td>245-507</td>
<td>0.022</td>
<td>0.519</td>
<td>0.207-1.300</td>
<td>0.161</td>
</tr>
<tr>
<td>≥80</td>
<td>21</td>
<td>572</td>
<td>461-683</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KAZALD1-expression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>36</td>
<td>660</td>
<td>467-853</td>
<td>0.000</td>
<td>4.096</td>
<td>1.843-9.106</td>
<td>0.001</td>
</tr>
<tr>
<td>High</td>
<td>22</td>
<td>295</td>
<td>184-406</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; KPS, Karnofsky performance status.

Figure 3. KAZALD1 expression correlates with glioma grade progression and prognosis. (A) The expression of KAZALD1 was significantly higher in high-grade glioma patients than in those with low-grade glioma (P<0.001). (B) High KAZALD1 expression had significantly shorter OS (P<0.001) than low expression in high-grade glioma patients.

Discussion

In the present study, we investigated the methylation and expression level of KAZALD1 in two independent cohorts, totaling 210 glioma patients. We found that methylation level of KAZALD1 promoter was associated with glioma grade progression and overall survival (OS) in high-grade gliomas using genome-wide DNA methylation profiling. We further compared the expression level of KAZALD1 in low-grade (astrocytoma, oligodendrocytoma and oligoastrocytoma) and high-grade (anaplastic gliomas and glioblastomas) human gliomas, and demonstrated a significant increase in KAZALD1 expression from low- to high-grade gliomas. KAZALD1 was an independent prognostic factor predicting OS in high-grade gliomas, indicating a significant correlation between KAZALD1 expression and clinical outcome in glioma patients. KAZALD1 functional analyses were performed in LN229 and U251 cell lines, which showed KAZALD1 promoted invasion and proliferation of glioma both in vitro and in vivo. To the best of our knowledge, this is the first report on the methylation status, expression difference and function of KAZALD1 in glioma.
DNA methylation of promoter CpG islands has been recognized as an important mechanism for the regulation of gene expression and transcriptional modification in mammals. DNA methylation status is more stable and can be detected using a number of high-throughput and sensitive techniques with little patient material. Aberrations in DNA methylation patterns may have critical effects on tumor initiation and progression. Although considerable research has been conducted on the epigenetic control of tumor suppressor genes, little is known about the potential role of promoter CpG demethylation in the activation of oncogenes. In the
present study, we performed genome-wide DNA methylation profiling of 119 glioma tissues via microarrays. We set a series of screening conditions including grade correlation, survival correlation and CpG island in upstream of gene promoter (Fig. 1). KAZALDI was one of six genes conformed to appeal conditions. We also found that methylation level of KAZALDI in high-grade glioma was significantly lower than that in low-grade glioma (Fig. 2A). Kaplan-Meier survival curve analysis showed that low methylation level of KAZALDI had shorter OS compared to the high methylation group in high-grade glioma patients (Fig. 2B). Multivariate analysis identified hypomethylation of KAZALDI was an independent unfavorable prognostic factor for OS (Table I; P=0.009; low methylated group, 544 days; high methylated group, 958 days).

To explore whether the expression level of KAZALDI correlated with the status of methylation in glioma, we detected the KAZALDI expression in 91 independent cohorts including 30 low-grade and 61 high-grade glioma patients using immunohistochemistry. We found that high-grade glioma patients had significantly higher KAZALDI expression than low-grade glioma patients (Figs. 3A and 4). According to our original hypothesis, there was a negative correlation between KAZALDI expression and methylation status in low- and high-grade gliomas. In 61 high-grade glioma patients, patients with high KAZALDI expression had shorter OS than those with low expression (Fig. 3B, Table II). These observations indicated that glioma with KAZALDI hypomethylation and higher protein expression might be a more biologically aggressive phenotype than those without it. These results showed that increased expression of KAZALDI in gliomas with a poor prognosis was at least partially due to hypomethylation of the KAZALDI promoter region.

To date, no information has been provided regarding the regulation of the KAZALDI gene in gliomas. However, rather limited data are available on the relationship between the KAZALDI gene and its precise mechanism of action on tumors, and their clinical effect on outcome for patients with glioma remains unclear. The function of KAZALDI in dental development and bone regeneration was investigated only recently and, thus far, its biological function is unknown (17). The KAZALDI insulin-like factor binding domain has high affinity for insulin-like growth factors, while the Kazal domain contains sequence and structural homology to serine proteases and follistatins (15). The immunoglobulin-like domain contains sequence and structural homology to serine proteases and follistatins (15). The KAZALDI insulin-like factor binding domain has high affinity for insulin-like growth factors, while the Kazal domain contains sequence and structural homology to serine proteases and follistatins (15). The immunoglobulin-like domain contains sequence and structural homology to serine proteases and follistatins (15).

In summary, promoter hypomethylation of KAZALDI was associated with high KAZALDI expression. Patients harboring hypomethylation and high expression KAZALDI had shorter OS in high-grade glioma. On the basis of these observations and the results from subset analysis, it is reasonable to conclude that KAZALDI promoter methylation status is an important prognostic biomarker in glioma. KAZALDI promoted glioma malignant progression through invasion and proliferation.

Acknowledgements

The authors thank Dr Susan Furness for her critical reading and Professor Chen (Beijing Sanbo Brain Hospital) for IHC technical support. This study was supported by grants from the National High Technology Research and Development Program (no. 2012AA02A508), the International Science and Technology Cooperation Program (no. 2012DFA30470), the National 973 program (no. 2011CB707804) and the National Natural Science Foundation of China (no. 81201993).

References


